Zeta: Waiting For The ARPU Growth Reaccelerating

Zeta Global reported Q3 revenue up 26% year-over-year, beating consensus, while adjusted EBITDA jumped 51%; however ARPU growth slowed materially. Management raised 2025 guidance and provided an initial 2026 outlook, citing Athena AI product innovation and the Marigold acquisition as key growth drivers, with operating leverage and an expanding customer base supporting a bullish long-term thesis. The stock has drifted down ~3% over the past three months (versus a 6% S&P rise) but remains roughly 50% above the level when the prior coverage began.

Analysis

Market structure: ZETA’s beat (+26% rev, +51% adj EBITDA) benefits martech/cloud-native CRM and AI-enabled customer data platforms (ZETA, HUBS, CRM) while pressuring pure adtech (TTD, DSPs) if ARPU lags. The Marigold acquisition and Athena AI signal higher TAM and potential pricing power, but reaccelerating ARPU (target >+10% YoY) is the hinge for margin expansion versus continued unit-economics compression. Supply/demand: demand for first‑party data and AI marketing stacks is rising while privacy rules tighten supply of third‑party signals, favoring vendors with strong identity/product integration. Cross-asset: improved EBITDA supports credit metrics (narrower spreads), lowers tail risk for equity, increases option-call skew if market prices asymmetric upside from AI wins.

Risk assessment: tail risks include US/EU privacy regulation (could reduce addressability by >15%), failed Marigold integration producing 200–400bps margin drag, or loss of a top-5 customer causing >10% revenue hit. Immediate (days): price volatility around near-term disclosures; short-term (weeks/months): guidance cadence and Athena proof-points; long-term (12–36 months): whether AI drives sustainable ARPU lift. Hidden dependencies: sensitivity to ad spend cycles and identity-resolution partners; second-order risk is higher churn if ARPU monetization misfires. Key catalysts: next quarterly report (30–60 days), Athena adoption metrics, 2026 execution milestones.

Trade implications: constructive but size-constrained — operational leverage supports a modest long with defined risk management while options can express asymmetric upside. Direct play: establish 2–3% long ZETA for 12–18 months while using 12–18 month call spreads to cap premium. Relative/value: long ZETA vs short TTD or RAMP to isolate martech AI upside vs adtech cyclicality; rebalance if spread moves >25% or after 12 months. Sector rotation: trim pure adtech exposure and overweight martech/CRM names for 6–18 months.

Contrarian angles: consensus bullishness underestimates ARPU reacceleration dependency — if Athena yields even +5–10% incremental ARPU in 2026, EBITDA could re-rate by 30–50%; conversely the market may be underpricing integration/regulatory risk leading to abrupt repricing. Historical parallel: CRM vendors that executed AI roadmaps (Salesforce era) saw multi-quarter re-ratings once proof-points arrived, but many peers also imploded on execution slips. Watch for unintended consequence of valuation chasing prior to material ARPU proof points — a miss could trigger a 20%+ downside.

Key Decisions for Investors

• Establish a 2–3% long position in ZETA (ZETA) as a tactical core holding over 12–18 months; target +30–40% total return if ARPU reaccelerates, hard stop at -15% from entry, add 50% size if next two quarters show ARPU >+10% YoY.
• Implement a relative-value pair: long ZETA 2% vs short TTD 1.5% (or RAMP 1.5%) to express martech/AI upside vs adtech cyclicality; cap pair holding to 3% net exposure and unwind if spread compresses/widens by >25% or after 12 months.
• Use options to express asymmetric upside: buy a Jan 2026 ZETA LEAP call spread sized to 0.5–1% notional (buy ~30% OTM, sell ~70% OTM) or, if willing to own, sell cash‑secured puts 10–15% below current market to acquire at a discount; close option exposure on an earnings miss or IV spike >50% vs 30‑day.
• Reduce 1–3% exposure to pure adtech cyclicals (e.g., TTD) over the next 3 months and rotate proceeds into martech/AI exposure (ZETA, HUBS, CRM); re-evaluate after next two quarterly results and Athena/Marigold integration KPIs are disclosed.